HNF1A-MODY 妊娠期血糖管理与妊娠结局回顾分析
该研究回顾性分析了 73 位确诊 HNF1A-MODY 父母的 183 名后代,其中母系遗传 142 名、父系遗传 41 名。结果显示母系遗传后代大于胎龄儿发生率更高,且与母亲血糖异常相关,胰岛素治疗可降低大于胎龄儿风险。研究建议对相关产科和新生儿团队进行针对性围产期风险告知。
要点
- HNF1A 突变父母的后代可见大于胎龄儿和新生儿低血糖。
- 母系遗传且母亲血糖异常时,大于胎龄儿和新生儿低血糖更常见。
- 胰岛素治疗较单纯饮食管理可降低大于胎龄儿发生率。
核心结论
- HNF1A 突变父母的后代可出现大于胎龄儿和新生儿低血糖。
- 这些围产期后果在母系遗传病例中更常见且更具临床意义。
- 建议向产科和新生儿团队告知相关围产期风险,以降低潜在并发症。
研究设计与样本
- 回顾性队列研究,纳入 73 位确诊 HNF1A-MODY 父母的 183 名后代。
- 其中母系遗传后代 142 名,父系遗传后代 41 名。
- 数据来自父母回忆和/或产科病历回顾。
- 收集变量包括降糖治疗、HbA1c、果糖胺、孕期增重、新生儿出生体重、胎龄、新生儿低血糖发生率及后代基因型。
主要发现
- 母系遗传后代大于胎龄儿发生率为 39.4%,父系遗传后代为 15%,p=0.012。
- 大于胎龄儿与母亲血糖异常相关,且与新生儿是否携带突变无关。
- 胰岛素治疗组大于胎龄儿发生率为 35.1%,饮食管理组为 64.3%,p=0.004。
- 胰岛素治疗妊娠的亚组分析中,大于胎龄儿与较高的平均毛细血管血糖相关,p=0.005,n=34。
- 在母系遗传且母亲血糖异常的病例中,持续性新生儿低血糖更多见,后代数为 8 比 0,p=0.067。
关键数值与推荐
- 母系遗传后代大于胎龄儿发生率为 39.4%,父系遗传后代为 15%,p=0.012。
- 胰岛素治疗组大于胎龄儿发生率为 35.1%,饮食管理组为 64.3%,p=0.004。
- 胰岛素治疗妊娠亚组中,大于胎龄儿与第三孕期胰岛素剂量相关,p=0.04,n=33。
- 胰岛素治疗妊娠亚组中,大于胎龄儿与 HbA1c 相关,p=0.04,n=34。
- 第三孕期体重校正的每日胰岛素总剂量为 0.61 单位/公斤/天,范围 0.49–0.62,n=26。
临床怎么用
- 对母系遗传 HNF1A-MODY 妊娠,应关注母亲血糖控制和大于胎龄儿风险。
- 胰岛素治疗可能比单纯饮食管理更有利于降低大于胎龄儿发生率。
- 围产期应重点监测新生儿低血糖,尤其是母系遗传且母亲血糖异常者。
局限性
- 数据来自父母回忆和/或产科病历回顾,可能存在回忆偏倚。
- 持续性新生儿低血糖组间比较的 p 值为 0.067,未达到常规显著性水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Introduction Birthweight of HNF1A-affected offspring is largely similar to the background population with rarely reported cases of large for gestational age (LGA) and neonatal hypoglycaemia (NH). Conventional clinical management of pre-gestational diabetes appears to be sufficient in managing HNF1A-affected women in pregnancy. This study aims to evaluate pregnancy outcomes and review glucose management in a cohort with HNF1A-MODY. Methodology This is a retrospective review of 183 offspring (142 maternal and 41 paternal) of 73 parents with confirmed HNF1A-MODY. Data were obtained from maternal/paternal recall and/or review of maternity charts. Variables included glycaemic treatment, HbA1c, fructosamine, gestational weight gain, neonatal birthweight, gestation, incidence of NH, and offspring genotype status. Results Maternal offspring had a higher incidence of LGA (39.4% vs. 15%, p = 0.012). LGA was associated with maternal dysglycaemia independent of neonatal mutation status. Rate of LGA was lower with insulin treatment compared to diet (35.1% vs. 64.3%, p = 0.004). Subgroup analysis of insulin treated pregnancies showed LGA was associated with higher mean capillary glucose (p = 0.005) (n = 34), third trimester insulin doses (p = 0.04) (n = 33), HbA1c (p = 0.04) (n = 34) and maternal gestational weight gain (p = 0.011) (n = 31). Weight adjusted total daily dose of insulin was 0.61 unit/kg/day (0.49–0.62) in Trimester 3 (n = 26). Persistent NH was more prevalent in maternally inherited cases with dysglycaemia (8 vs. 0 offspring, p = 0.067). Conclusion Large birthweight and NH occur in offspring of parents with HNF1A mutations. These sequelae are more frequent and clinically significant in maternally inherited cases. It is prudent to counsel relevant obstetric and neonatal teams around specific perinatal concerns to reduce potential morbidity.
引用
- Diabetes, Obesity and Metabolism:Glycaemic Management and Pregnancy Outcomes in HNF1A‐MODY
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。